Moreover, recent research identifies FBXO32 as a functional tumor suppressor, whereby re-expression of epigenetically silenced FBXO32 in ovarian cancer cells facilitates cell sensitivity to cisplatin (12). Here, FBXO32 is linked to ovarian carcinoma.